Patents


LP561A1 and the rest of products in development by Lipopharma are protected by five global "Patent Families", four of them owned by The University of the Balearic Islands (UIB) and licensed to Lipopharma and one owned by Lipopharma.

 


1) Patent based on the PCT application PCT/ES2002/00475, titled "Use of Hydroxyoleic acid and similar compounds in the production of medicaments". It has already been granted in all major markets, including Europe, USA, Japan, China, Russia, Mexico, Canada or Brazil. This patent is owned by the University of the Balearic Islands and Lipopharma has in-licensed exclusive worldwide rights.

::> Main patent information and documents related to PCT/ES2002/00475 can be accessed here

 


2) Patent based on the international application PCT/ES2009/070561, titled "Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug". It is currently undergoing national phases in all major markets. The priority Spanish patent was granted in Spain in 2011 and the initial patent application has now also been granted in most major markets, including Europe, USA, China, Russia, Mexico, Japan, South Korea, Australia, Canada, Chile or Israel. Different divisional/continuation applications are currently being pursued in all major markets in order to strengthen the protection for the key products and indications included in this patent family.

This patent is owned by the University of the Balearic Islands and Lipopharma has in-licensed exclusive worldwide rights. This is the main patent family protecting the current development in cancer with LP561A1 and it provides strong market protection until December 2029, with an additional 5 years extension possible in most territories.

::> Main patent information and documents related to PCT/ES2009/070561 can be accessed here

 


3) Patent based on the PCT application PCT/ES2010/070153, titled "Use of Derivatives of Polyunsaturated Fatty Acids as Medicaments", currently undergoing national phases in all major markets. The priority Spanish patent was granted in Spain in 2011 and PCT national phases have already been granted in almost all major markets, including Europe, USA, Russia, Mexico, Chile, Japan, Australia or South Korea. Different divisional/continuation applications are currently being pursued in all major markets in order to strengthen the protection for the key products and indications included in this patent family. This patent is owned by Lipopharma.

::> Main patent information and documents related to PCT/ES2010/070153 can be accessed here

 


4) Patent based on the PCT application PCT/ES2012/070697, titled "Use of Enantiomers of 2-hydroxyderivatives of Fatty Acids as Medicaments", currently undergoing national phases in several territories. The priority Spanish patent was granted in Spain in 2014. PCT National phases have already been granted in Europe, USA and Russia. Further national applications are currently under evaluation in different countries. This patent is owned by the University of the Balearic Islands and Lipopharma has licensed all worldwide rights in exclusive.

::> Main patent information and documents related to PCT/ES2012/070697 can be accessed here

 


5) Patent based on the international application PCT/EP2015/074321, titled “Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases”, currently undergoing national phases in several territories. Priority patent was granted in Europe in 2014. PCT National phases have already been granted in Europe, USA, Japan, Israel and Canada. Further national applications are currently under evaluation in different countries. This patent is owned by the University of the Balearic Islands and Lipopharma has licensed all worldwide rights in exclusive.

::> Main patent information and documents related to PCT/EP2015/074321 can be accessed here

© 2019 Lipopharma Therapeutics. All rights reserved | legal notice

Ctra. de Valldemossa Km. 7,4. ParcBIT. Edifici Disset. 2n. Mod. C-8. E07121 - Palma de Mallorca. Spain  | Phone/Fax: +34 971439886  |  Email: info@lipopharma.com

Login Form